TARGETING CD200/CD200R SIGNALING AS A NOVEL STRATEGY FOR THE TREATMENT OF THERAPY-RESISTANT PROSTATE CANCER

$1,446,009FY2025Defense Health AgencyDOD

University Of California, Davis

Investigators